• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

ramucirumab - Articles and news items


Ramucirumab improves progression-free survival in bladder cancer trial

Industry news / 28 September 2015 / Victoria White

Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +